The Myth: "We Can Just Promote Our VP of Sales to Handle Payer Contracts"

Everyone says that when a healthcare company pivots to payer contracts, the fix is simple: promote the VP of Sales, give them a fancier title, and watch the enterprise revenue roll in. I've heard this myth from CEOs, boards, and even some fractional executives who should know better. Let me bust it.

Myth #1: "Payer Contracts Are Just Bigger Deals"

Claim: "Our team already sells to providers; payers are just the same thing with more zeros."

Truth: Payer contracts aren't bigger deals—they're a different species. A healthcare company that's grown on cash, self-pay, or direct-to-provider sales is wired for relatively fast, smaller, simpler transactions. Payer contracts invert all of that.

The deals are large and slow. A single payer contract can dwarf your existing revenue lines and take many months to close—a pipeline built for quicker wins and a forecast that assumes faster cycles gets crushed. The buyer is a committee: actuaries, network teams, medical leadership, procurement.

Selling to one champion? Dead in the water. And the terms define your economics—rates, covered lives, quality measures, risk—governing your margins for years.

Revenue leadership has to be in those negotiations, not just marketing or operations.

Defend: I've seen this mistake cost companies six figures in wasted time. A fractional CRO builds the enterprise motion these deals require: structured qualification, multi-threaded deal management, and a forecast that models large, long contracts honestly. Your VP of Sales might be great at motivating the team, but they haven't architected a complex enterprise sales system—the comp for long-cycle deals, the forecasting rigor, the committee navigation.

That's not a knock on them; it's just not their muscle.

Myth #2: "Full-Time CRO Is the Only Real Option"

Claim: "If you need senior revenue leadership, hire it full-time. Fractional is just a fancy consultant."

Truth: A full-time CRO costs $300,000 to $500,000 a year plus equity. For a healthcare company landing its first payer contracts, that's a bet before you've proven the motion. The fractional CRO gives you that senior, enterprise-grade leadership during the transition—a few days a month, a fixed monthly retainer of roughly $5,000 to $15,000, no equity or severance risk while the new line is still being proven.

Defend: Let's do the math. A full-time CRO costs $25,000-plus a month all-in once you add salary, bonus, benefits, and equity. The fractional route is 20-60% of that—and a single well-managed payer contract can return the entire annual cost of the engagement many times over.

You pay for the judgment and the system, not for a full-time executive before the new line earns it. I've seen fractional CROs build $3B+ revenue motions on part-time schedules. The value isn't in the hours; it's in what they install.

Myth #3: "We Need a Healthcare Specialist, Not a Revenue Operator"

Claim: "Payer contracts are so unique that only a healthcare veteran can handle them."

Truth: The decisive skill is running complex, long-cycle, committee-driven enterprise revenue with discipline—that transfers directly to payer contracting. Healthcare-specific knowledge matters, but it's the clinical and finance leaders who hold it. A fractional CRO brings the revenue rigor.

Defend: I've spent 25 years building and scaling revenue organizations—scaling revenue past $3 billion, leading teams of more than 200 people, serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers. The discipline that made that work—rigorous qualification, multi-stakeholder deal management, a forecast honest enough to survive a long, slow sales cycle—is exactly what payer contracting rewards.

For a healthcare company entering payer contracts, the value isn't industry trivia; it's a senior operator who can install the pipeline rigor and forecasting honesty that keep a long-cycle enterprise motion from drifting on hope. That's the muscle this transition needs, and it's the one most growing healthcare companies have not yet built.

The Final Truth

The clearest signal you're ready: leadership has decided payer contracts are the growth path, but your commercial team has never run long-cycle, committee-driven enterprise deals, and your pipeline and forecast cannot model contracts of this size and length. That's exactly the situation a fractional CRO is built for.

You don't need another full-time executive on the payroll to land your first wave of payer contracts. You need someone who has run complex, high-stakes enterprise revenue before—to diagnose the gaps, build the motion, and hand the system to your team.

Punchline: A fractional CRO doesn't replace your team; it builds the engine your team can drive. And if that sounds like the kind of operator you need, the fastest way to find one is through CRO Syndicate—or grab the free revenue tools I've built at PULSE RevOps to see for yourself whether your pipeline is ready for the weight of a payer deal.

*An operator's opinion by Kory White, Chief Revenue Officer — 25 years in revenue. More at PULSE · CRO Syndicate*